Lercanidipine Hydrochloride Glenmark

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hydrochloride Glenmark, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercanidipine Hydrochloride Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure. It helps achieve target blood pressure levels and reduces cardiovascular risk. Hypertension: lowers systolic and diastolic blood pressure to recommended targets. Isolated systolic hypertension: reduces elevated systolic pressure in older adults. Diastolic hypertension: decreases high diastolic pressure in younger patients.

Lercanidipine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually resolves with continued therapy. - Peripheral edema: swelling of ankles or lower legs, typically mild. - Dizziness: may occur when standing quickly. - Nausea: occasional stomach upset. - Tachycardia: slight increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat, potentially airway‑compromising. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes indicating liver stress. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythms in susceptible individuals.

Before initiating therapy with Lercanidipine Hydrochloride, certain precautions should be observed to ensure safe use. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: start at lower doses and monitor for dizziness. - Concomitant antihypertensives: adjust therapy to prevent additive blood pressure lowering. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risking severe hypotension. - Grapefruit juice: can elevate drug concentration, leading to exaggerated effects. - Other potent antihypertensives: combined use may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - NSAIDs: can blunt antihypertensive response. - Diuretics: monitor electrolytes and volume status. - Beta‑blockers: observe heart rate and blood pressure for additive effects. - Lipid‑lowering agents (e.g., statins): watch for increased statin levels.